Anti-Integrin alpha 6 [MP4F10]
Invented at Cancer Research UK London Research Institute: Lincoln's Inn Fields
- Datasheet
- References (11)
- Inventor Info
Info
Catalogue Number | 151134 |
Applications | FACS IHC IF IP WB ICC |
Antigen/Gene or Protein Targets | Integrin alpha6 (CD49f) |
Reactivity | Human |
Relevance | Integrins are heterodimeric cell surface receptors composed of alpha and beta subunits, which mediate cell-cell and cell-extracellular matrix attachments. Aberrant integrin expression has been found in many epithelial tumours. Changes in integrin expression have been shown to be important for the growth and early metastatic capacity of melanoma cells. Integrin alpha 6 is found on epithelial and endothelial basement membranes and colorectal carcinoma. Integrin alpha 6 associates with integrin beta 4 to form integrin a6b4, one of the most abundant keratinocyte integrins, and binds laminin. MP 4F10 may be used in clinical studies for tumour grading as it will stain both moderately and well-differentiated colorectal adenocarcinoma. |
Host | Mouse |
Immunogen | SW1222 human colorectal cell line. |
Subclass | IgG1 kappa |
Subclass Notes | Inconclusive results |
Myeloma Used | P3/NS1/1-Ag4.1 |
Recommended Growing Conditions | DMEM + 5% FCS |
Strain | Balb/c |
Notes |
This antibody has been tested and active in: Inhibition of adhesion of human colon carcinoma cell line avidin-biotin complex staining in human infant breast tissue indirect immunoperoxidase staining in human colorectal carcinoma, human SW1222 cell line GAG-ELISA of human type I collagen, type IV fibronectin and laminin, human colorectal adenocarcinoma This antibody was tested in an indirect immunoperoxidase staining and found to NOT bind: human: intestine, placenta, skin, cervix, breast, endometrium, vagina, kidney, spleen, heart, smooth muscle and skeletal muscle |
Research Area | Adhesion, Developmental Biology, Stem Cell Biology |
References: 11 entries
Zhou et al. 2019. Stem Cell Res Ther. 10(1):155. PMID: 31151466.
Pieri et al. 2019. Stem Cell Res Ther. 10(1):135. PMID: 31109365.
Kapsokalyvas et al. 2017. Colloids Surf B Biointerfaces. 159:97-107. PMID: 28780465.
IHC
Zhang et al. 2017. PLoS One. 12(2):e0172207. PMID: 28234938.
Zhang et al. 2016. Cell Reprogram. 18(6):401-410. PMID: 27906584.
Al Thawadi et al. 2016. Oncotarget. 7(5):5289-305. PMID: 26700621.
WB
Stempin et al. 2015. Cancer Cell Int. 15:110. PMID: 26612978.
IF ICC
Svensson Månsson et al. 2007. J Pathol. 212(1):102-11. PMID: 17370299.
Levy et al. 2000. Mol Biol Cell. 11(2):453-66. PMID: 10679006.
Anbazhagan et al. 1995. J Pathol. 176(3):227-32. PMID: 7674085.
Pignatelli et al. 1990. Proc Natl Acad Sci U S A. 87(4):1541-5. PMID: 2304917.
Add a reference
References: 11 entries
Zhou et al. 2019. Stem Cell Res Ther. 10(1):155. PMID: 31151466.
Pieri et al. 2019. Stem Cell Res Ther. 10(1):135. PMID: 31109365.
Kapsokalyvas et al. 2017. Colloids Surf B Biointerfaces. 159:97-107. PMID: 28780465.
IHC
Zhang et al. 2017. PLoS One. 12(2):e0172207. PMID: 28234938.
Zhang et al. 2016. Cell Reprogram. 18(6):401-410. PMID: 27906584.
Al Thawadi et al. 2016. Oncotarget. 7(5):5289-305. PMID: 26700621.
WB
Stempin et al. 2015. Cancer Cell Int. 15:110. PMID: 26612978.
IF ICC
Svensson Månsson et al. 2007. J Pathol. 212(1):102-11. PMID: 17370299.
Levy et al. 2000. Mol Biol Cell. 11(2):453-66. PMID: 10679006.
Anbazhagan et al. 1995. J Pathol. 176(3):227-32. PMID: 7674085.
Pignatelli et al. 1990. Proc Natl Acad Sci U S A. 87(4):1541-5. PMID: 2304917.
Add a reference